Grit Biotechnology

This early-stage study is testing a new cell-based treatment called GT801 injection for people with moderate-to-severe autoimmune diseases that haven't responded to standard medications. The trial will enroll 22 adults with specific conditions like lupus, myositis, or scleroderma…

This is an early-stage safety study testing a new personalized cell therapy called GT101. It involves collecting a patient's own immune cells from a tumor, growing large numbers of them in a lab, and then infusing them back into the patient to fight their cancer. The main goal is…

This early-stage study is testing whether a new cell injection called GT729 is safe and might help control chronic graft-versus-host disease (cGVHD). The trial includes adults aged 18-65 who have cGVHD that hasn't responded to at least two previous treatments and who still need i…

This early-stage study is testing the safety of a new, personalized treatment for advanced head and neck cancer. Doctors take a patient's own immune cells from a tumor, grow large numbers of them in a lab, and infuse them back into the patient along with a standard immunotherapy …

This early-stage study is testing the safety of an experimental cell therapy called GT719 injection in people with severe autoimmune diseases like lupus, scleroderma, and inflammatory muscle diseases that haven't improved with standard medications. The trial will enroll 10 partic…

This early-phase study is testing a new cell therapy called GT801 in adults with advanced blood cancers or autoimmune anemia that has not responded to standard treatments. The main goals are to check if the treatment is safe and to see early signs of whether it helps control the …

This early-stage study is testing a new cell therapy called GT719 in adults with several types of immune-mediated kidney diseases that have not responded well to standard treatments. The main goals are to find a safe dose and see how well the body tolerates the treatment, while a…

This early-stage study is testing a new, 'off-the-shelf' cell therapy called GT719 in adults with B-cell blood cancers (like certain leukemias and lymphomas) that have come back or not responded to other treatments. The main goals are to see if the treatment is safe, what side ef…

This is an early-stage study to test the safety and initial effects of a new cell therapy called GT719. It is for adults with neurological autoimmune diseases that have come back or not improved with standard treatments. Researchers will give participants an infusion of GT719 cel…

This study is testing a new personalized cell therapy called GT307 for adults with advanced solid tumors that have not responded to standard treatments. Doctors take a patient's own immune cells from a tumor, grow large numbers of them in a lab, and then infuse them back into the…

This early-stage study is testing a new cell-based treatment called GT719 injection for adults with B-cell blood cancers that have come back or haven't responded to other treatments. The main goals are to find a safe dose and see if the treatment helps shrink the cancer. About 46…